Alnylam Pharmaceuticals, Inc. vs Johnson & Johnson
ALNY vs JNJ — side-by-side comparison from reported financials. ALNY leads 3, JNJ leads 6 of 9 comparable metrics.
Alnylam Pharmaceuticals, Inc.
ALNY · Healthcare
$232.60+3.59%Strong
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | ALNY | JNJ |
|---|---|---|
| Price | $232.60 | $261.79 |
| Market cap | $31.1B | $631B |
| Revenue (TTM) | $4.80B | $97.9B |
| Revenue growth | +53.0% | +5.6% |
| Net margin | 16.8% | 21.5% |
| Free cash flow | $794M | $22.2B |
| Net cash (debt) | — | ($27.8B) |
| 1-year price return | -49.1% | +37.0% |
| P/E | 38.5 | 29.9 |
| P/E vs own history (cheap-side %) | 92% | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | 94% | 26% |
| Altman Z-score | 4.40 | — |
| CV checks passed | 8 of 10 | 10 of 10 |
| Employees | 2,500 | 140,800 |
Full résumé-style profiles: ALNY CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.